Skip to content

Oruka Therapeutics, Inc. ORKA Other income, net (Note 6)

Other income, net (Note 6) at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
-$32M+90.6%
Kymera Therapeutics logo
Kymera TherapeuticsKYMR
$14.92M+68.7%
Protagonist Therapeutics logo
Protagonist TherapeuticsPTGX
$53K-35.4%
Alumis Inc. logo
Alumis Inc.ALMS
$7K+116%
Johnson & Johnson logo
Johnson & JohnsonJNJ
AbbVie logo
AbbVieABBV

Other financials

Income statement

See full
Revenue-
Operating income-$36.4M-45.2%
Net income-$31.8M-51.5%
EPS (diluted)-$0.46+93.4%

Balance sheet

See full
Cash & equivalents$49.5M-40.7%
Total debt$1.8M+90.8%
Total equity$486.7M+33.4%
Total assets$504.5M+33.8%

Cash flow

See full
Operating cash flow-$23.6M-13.0%
CapEx$73.0K+462%
Free cash flow-$23.7M-13.3%

Valuation

See full
Market cap$5.03B+533%

Returns & leverage

See full
Return on equity-27.3%-11.1pp
Debt / equity0.0×
Current ratio23.8×-6.3×

Where this comes from

Reported directly by Oruka Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:OtherNonoperatingIncomeExpense.

The official record: Oruka Therapeutics, Inc.’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Oruka Therapeutics, Inc.'s other income, net (note 6).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Oruka Therapeutics, Inc.'s other income, net (note 6)?
Oruka Therapeutics, Inc. (ORKA) reported other income, net (note 6) of $8K in Q1 2026.
What does other income, net (note 6) mean?
This captures miscellaneous financial items that fall outside the scope of core operating activities, such as foreign exchange gains or losses, minor investment income, or non-recurring legal settlements. It serves as a catch-all for peripheral financial events that do not stem from the primary business operations. Investors monitor this to isolate core earnings from transient or incidental financial fluctuations.